ð¡æ°åã³ãããŠã€ã«ã¹ææçãšèªç¥æ©èœïŒäžåœã§ã®ææ°ç ç©¶
æ°åã³ãããŠã€ã«ã¹ææçïŒCOVID-19ïŒã¯ãç§ãã¡ã®ç掻ã«å€å²ã«ããã圱é¿ãäžããŠããŸãããææçãã®ãã®ã®çç¶ã ãã§ãªããå埩åŸãç¶ãæ§ã ãªçç¶ããããããåŸéºçããäžçäžã§å ±åãããŠããŸãããã®äžã§ãç¹ã«æ³šç®ãããŠããã®ããæèåã®äœäžãéäžåã®æ¬ åŠãç©å¿ããšãã£ãèªç¥æ©èœã®é害ãéç§°ããã¬ã€ã³ãã©ã°ãã§ãã
ãããŸã§ã欧米ãäžå¿ã«ã³ããåŸã®èªç¥æ©èœã«é¢ããç ç©¶ãé²ããããŠããŸããããäžåœã«ãããå€§èŠæš¡ãªèª¿æ»ã¯äžè¶³ããŠããŸãããç¹ã«ãææåã®åŒ·ããªãã¯ãã³æ ªãæµè¡ããææã«ãäžåœã®äººã ãã©ã®ãããªèªç¥æ©èœã®å€åãçµéšããã®ãã¯ãéèŠãªèª²é¡ã§ãããä»åã玹ä»ããç ç©¶ã¯ãäžåœã§ãã³ãããã¯èŠå¶ãç·©åãããåŸã®ãªãã¯ãã³æ ªæµè¡æã«ãCOVID-19ã«çœ¹æ£ãã人ã ã®èªç¥æ©èœã®ç¶æ ãšããã®ãªã¹ã¯èŠå ãæããã«ãããã®ã§ãããã®ç ç©¶çµæã¯ãç§ãã¡èªèº«ã®å¥åº·ç®¡çããä»åŸã®å»çäœå¶ãèããäžã§è²Žéãªç€ºåãäžããŠãããŸãã
ð¬ç ç©¶ã®æ¹æ³ïŒå€§èŠæš¡ãªã³ã©ã€ã³èª¿æ»ã§äœãåãã£ããïŒ
ç ç©¶ã®èæ¯ãšç®ç
äžåœã§ã¯ã峿 Œãªãã³ãããã¯å¯Ÿçãç·©åãããåŸãå€ãã®äººã ãCOVID-19ã«ææããŸããããã®ææã«æµè¡ã®äžå¿ãšãªã£ãã®ã¯ããªãã¯ãã³æ ªã§ãããããããã®ãªãã¯ãã³æ ªææãäžåœã®äººã ã®èªç¥æ©èœã«ã©ã®ãããªåœ±é¿ãäžããã®ããäœç³»çãªèª¿æ»ã¯è¡ãããŠããŸããã§ãããããã§ãæ¬ç ç©¶ã¯ããªãã¯ãã³æ ªæµè¡æã«COVID-19ã«çœ¹æ£ããæ£è ã®ãäºæ¥æ§æãïŒçºçåŸ3ã¶ææªæºã®æéïŒã«ãããèªç¥æ©èœãè©äŸ¡ãããã®äœäžã«é¢é£ãããªã¹ã¯èŠå ãç¹å®ããããšãç®çãšããŸããã
調æ»å¯Ÿè±¡ãšæé
ãã®ç ç©¶ã¯ã2023幎1æ15æ¥ãã29æ¥ã«ãããŠãäžåœå šåã§ã¹ããŒããã©ã³ãçšãããªã³ã©ã€ã³èª¿æ»ãšããŠå®æœãããŸãããåèš9663人ã®åå è ãç»é²ããããã®ãã¡8905人ïŒå šäœã®92.2%ïŒãCOVID-19ã«çœ¹æ£ããçµéšã®ãã人ã ã§ããããã®å€§èŠæš¡ãªããŒã¿åéã«ãããåºç¯ãªäžåœã®äººã ã®ç¶æ³ãææ¡ããããšãå¯èœãšãªããŸããã
èªç¥æ©èœã®è©äŸ¡æ¹æ³
åå è ã®èªç¥æ©èœãè©äŸ¡ããããã«ã以äžã®2ã€ã®ãã¹ããçšããããŸããã
- Integrated Cognitive Assessment (ICA)ïŒçµ±åèªç¥è©äŸ¡ãããã¯ãèšæ¶åãæ³šæéäžåãæ å ±åŠçé床ãªã©ãè€æ°ã®èªç¥æ©èœãç·åçã«è©äŸ¡ããããã®ãã¹ãã§ãã
- Number Ordering Test (NOT)ïŒæ°åé åºä»ããã¹ããããã¯ãäœæ¥èšæ¶ã泚æã®åãæ¿ããèšç»èœåãšãã£ãå®è¡æ©èœãè©äŸ¡ããã®ã«åœ¹ç«ã¡ãŸãã
ãããã®å®¢èгçãªèªç¥æ©èœãã¹ãã«å ããŠãåå è èªèº«ãæããèªç¥æ©èœã®äžèª¿ïŒäž»èгçèªç¥æ©èœã®èšŽãïŒã«ã€ããŠã詳现ã«å°ããããŸããã
ðç ç©¶ã®äž»ãªãã€ã³ãïŒå®¢èгçè©äŸ¡ãšäž»èгç蚎ã
äž»èŠãªçµæã®æŠèŠ
æ¬ç ç©¶ã§ã¯ãCOVID-19眹æ£è ã®èªç¥æ©èœã«ã€ããŠã客芳çãªãã¹ãçµæãšãæ£è èªèº«ãæãã䞻芳çãªèšŽãã®äž¡é¢ããåæãè¡ãããŸããããã®çµæãè峿·±ãéããæããã«ãªããŸããã
| è©äŸ¡é ç® | å 容 | COVID-19眹æ£åŸã®å²å/çµæ | è£è¶³äºé |
|---|---|---|---|
| 䞻芳çèªç¥æ©èœã®èšŽã | æèã®æè»æ§ã®æ¬ åŠ | 65.5% (5832人) | å埩åŸã«å€ãã®äººãå ±å |
| æ å ±åŠçé床ã®äœäž | 60.9% (5419人) | å埩åŸã«å€ãã®äººãå ±å | |
| äžç ç | 48.8% (4344人) | å埩åŸã«å€ãã®äººãå ±å | |
| 客芳çèªç¥æ©èœã®è©äŸ¡ | ç¥çµå¿çåŠçæ€æ»ã®æçžŸ | ã»ãšãã©ã®é ç®ã§æçžŸäžè¯ | çµ±èšçã«ææãªå·® (P<0.05) |
| ICAæ£çç | 瀟äŒäººå£çµ±èšåŠçèŠå 調æŽåŸãäœã | çµ±èšçã«ææãªå·® (P<0.05)ããã ã圱é¿ã¯éåžžã«å°ãã (partial η2â€0.001) |
ãã®è¡šãããããããã«ãCOVID-19ããå埩ãã人ã ã®å€ããããæèã®æè»æ§ã®æ¬ åŠãããæ å ±åŠçé床ã®äœäžããšãã£ã䞻芳çãªèªç¥æ©èœã®äžèª¿ã蚎ããŠããŸããããŸããçŽåæ°ã®äººãäžç çãå ±åããŠããŸãã
äžæ¹ã§ã客芳çãªç¥çµå¿çåŠçæ€æ»ïŒè³ã®æ©èœãèšæ¶ã泚æãèšèªãªã©ãè©äŸ¡ãããã¹ãïŒã§ã¯ãCOVID-19眹æ£è ã¯ã»ãšãã©ã®é ç®ã§æçžŸãæªãåŸåãèŠãããŸãããããããå¹Žéœ¢ãæ§å¥ãåŠæŽãšãã£ã瀟äŒäººå£çµ±èšåŠçèŠå ãèæ ®ããŠåæãããšãICAïŒçµ±åèªç¥è©äŸ¡ïŒã®æ£ççã®ã¿ãçµ±èšçã«ææã«äœããšããçµæã«ãªããŸããããã®ãææãªå·®ãã¯èªãããããã®ã®ããã®åœ±é¿ã®åºŠåããç€ºãææšïŒpartial η2ïŒã¯éåžžã«å°ãããå šäœãšããŠã®å®¢èгçãªèªç¥æ©èœãžã®åœ±é¿ã¯è»œåŸ®ã§ããå¯èœæ§ã瀺åãããŸããã
èªç¥æ©èœäœäžã®ãªã¹ã¯èŠå
ããã«ç ç©¶ã§ã¯ãèªç¥æ©èœã®æçžŸäžè¯ãšææã«é¢é£ããèŠå ãç¹å®ãããŸãããå ·äœçã«ã¯ã以äžã®ç¹åŸŽãæã€äººã ããèªç¥æ©èœã®å€åã«å¯ŸããŠããè匱ã§ããããšã瀺ãããŸããã
- 女æ§
- é«éœ¢è
- äœåŠæŽè
- äžåœå西éšã«å± äœãã人ã
- äžç çãæ±ãã人ã
ãããã®èŠå ã¯ãäž»èŠãªç¥çµå¿çåŠççµæã®æçžŸäžè¯ãšçµ±èšçã«ææãªé¢é£ãããããšã倿ããŸããïŒP<0.05ïŒãç¹ã«ãäžç çã¯èªç¥æ©èœã«å€§ããªåœ±é¿ãäžããå¯èœæ§ã瀺åãããŠããŸãã
ð§ç ç©¶çµæããèŠããŠããããšïŒèå¯
ãã®ç ç©¶çµæã¯ãCOVID-19åŸã®èªç¥æ©èœã«ã€ããŠãããã€ãã®éèŠãªç€ºåãäžããŠãããŸãã
䞻芳ç蚎ããšå®¢èгçè©äŸ¡ã®ä¹é¢
æã泚ç®ãã¹ãç¹ã¯ãå€ãã®äººã ã䞻芳çãªèªç¥æ©èœã®äžèª¿ã蚎ããŠããäžæ¹ã§ã客芳çãªèªç¥æ©èœãã¹ãã§ã¯ã瀟äŒäººå£çµ±èšåŠçèŠå ã調æŽãããšãã®å·®ãéåžžã«å°ãããªããšããçµæã§ããããã¯ãããã¬ã€ã³ãã©ã°ãã®ãããªäž»èгçãªçç¶ããå¿ ãããæšæºçãªèªç¥æ©èœãã¹ãã§æç¢ºã«æããããªãå¯èœæ§ãããããšã瀺åããŠããŸãã
èããããçç±ãšããŠã¯ã以äžã®ãããªç¹ãæããããŸãã
- èªå·±èªèã®ãã€ã¢ã¹ïŒææãçµéšããããšã§ãèªèº«ã®äœèª¿ãèªç¥æ©èœã«éæã«ãªã£ãŠããå¯èœæ§ããããŸãã
- æ€æ»ã®æåºŠïŒäœ¿çšããã客芳çãã¹ãããæ¥åžžçæŽ»ã§æãã埮åŠãªèªç¥æ©èœã®å€åãæããã«ã¯ååãªæåºŠãæã£ãŠããªãã£ãå¯èœæ§ããããŸãã
- æ¥åžžç掻ãžã®åœ±é¿ïŒããšã客芳çãªãã¹ãã§å€§ããªå·®ãåºãªããŠããæ¬äººãæããäžèª¿ãæ¥åžžç掻ãä»äºã®ããã©ãŒãã³ã¹ã«åœ±é¿ãäžããããšã¯ååã«ããåŸãŸãã
ãã®ä¹é¢ã¯ãCOVID-19åŸéºçã®è©äŸ¡ã«ãããŠãå®¢èŠ³çææšã ãã§ãªããæ£è ã®äž»èгçãªèšŽãã«è³ãåŸããããšã®éèŠæ§ãæ¹ããŠæµ®ã圫ãã«ããŠããŸãã
è匱ãªãµãã°ã«ãŒããžã®åœ±é¿
ç ç©¶ã¯ãå šäœãšããŠã®å®¢èгçãªåœ±é¿ã¯è»œåŸ®ã§ãããã®ã®ãç¹å®ã®ãµãã°ã«ãŒãïŒå¥³æ§ãé«éœ¢è ãäœåŠæŽè ãäžç çæ£è ïŒãèªç¥æ©èœã®å€åã«å¯ŸããŠããæåæ§ãé«ãããšãæããã«ããŸãããããã¯ãCOVID-19åŸã®ã±ã¢ãæ¯æŽãèããäžã§éåžžã«éèŠãªæ å ±ã§ãã
- 女æ§ïŒå¥³æ§ãç·æ§ãããèªç¥æ©èœã®äžèª¿ã蚎ããããããããã¯å®éã«åœ±é¿ãåããããã¡ã«ããºã ãããã®ãããããŸããã
- é«éœ¢è ïŒå 霢ã«äŒŽãèªç¥æ©èœã®äœäžã«ãCOVID-19ãããã«æè»ããããå¯èœæ§ããããŸãã
- äœåŠæŽè ïŒèªç¥äºååïŒè³ããã¡ãŒãžãåããŠãæ©èœãç¶æã§ããèœåïŒãäœãå¯èœæ§ãããã圱é¿ãåãããããšèããããŸãã
- äžç çæ£è ïŒäžç çã¯ãããèªäœãèªç¥æ©èœã«æªåœ±é¿ãäžããããšãç¥ãããŠããŸããCOVID-19åŸã®äžç çããèªç¥æ©èœã®äœäžãããã«æªåãããŠããå¯èœæ§ãé«ãã§ãããã
ãããã®è匱ãªã°ã«ãŒãã«å¯ŸããŠã¯ããããã现ãããªã¹ã¯ãªãŒãã³ã°ãä»å ¥ãå¿ èŠãšãªãã§ãããã
ãäºæ¥æ§æããšããæéã®éèŠæ§
ãã®ç ç©¶ã¯ãCOVID-19çºçåŸ3ã¶ææªæºã®ãäºæ¥æ§æãã«çŠç¹ãåœãŠãŠããŸãããã®ææã¯ãæ¥æ§æã®çç¶ãæ²»ãŸããå埩ã«åããäžæ¹ã§ãåŸéºçãåºçŸããããæéã§ããããŸãããã®ææã«èªç¥æ©èœã®å€åãæããããšã¯ãé·æçãªåœ±é¿ãäºæž¬ããæ©æä»å ¥ã®æ©äŒãèŠåºãäžã§éåžžã«éèŠã§ãã
ð¡å®ç掻ãžã®ã¢ããã€ã¹ïŒã³ããåŸã®èªç¥æ©èœã®ããã«ã§ããããš
ä»åã®ç ç©¶çµæãèžãŸããCOVID-19ã«çœ¹æ£ããçµéšãããæ¹ãç¹ã«ãªã¹ã¯èŠå ã«åœãŠã¯ãŸãæ¹ããå®ç掻ã§èªç¥æ©èœãè¯å¥œã«ä¿ã€ããã«ã§ããããšãããã€ãã玹ä»ããŸãã
- 質ã®è¯ãç¡ç ã確ä¿ããïŒäžç çã¯èªç¥æ©èœäœäžã®å€§ããªãªã¹ã¯èŠå ã§ããèŠåæ£ããç¡ç ç¿æ £ãå¿ãããå¯å®€ç°å¢ãæŽããã«ãã§ã€ã³ãã¢ã«ã³ãŒã«ã®æåãæ§ãããªã©ãç¡ç è¡çãæ¹åããŸããããå¿ èŠã§ããã°ãå»åž«ã«çžè«ããŠé©åãªæ²»çãåããããšã倧åã§ãã
- è³ã掻æ§åããæŽ»åãç¶ããïŒèªæžãããºã«ãæ°ããè¶£å³ã®åŠç¿ãèªåŠåŠç¿ãªã©ãé ãäœ¿ãæŽ»åãç©æ¥µçã«åãå ¥ããŸããããè³ã®æŽ»æ§åã¯ãèªç¥æ©èœã®ç¶æã»åäžã«åœ¹ç«ã¡ãŸãã
- ãã©ã³ã¹ã®åããé£äºãšé©åºŠãªéåïŒå¥åº·çãªé£ç掻ã¯ãè³ã®å¥åº·ã«ãçŽçµããŸããç¹ã«ãæé žåäœçšã®ããéèãæç©ããªã¡ã¬3èèªé žãå€ãå«ãéãªã©ãæèããŠæããŸãããããŸãããŠã©ãŒãã³ã°ã軜ããžã§ã®ã³ã°ãªã©ã®æé žçŽ éåã¯ãè³è¡æµãæ¹åããèªç¥æ©èœã®ç¶æã«å¹æçã§ãã
- ã¹ãã¬ã¹ã管çããïŒã¹ãã¬ã¹ã¯ãéäžåãèšæ¶åã«æªåœ±é¿ãåãŒããŸãããªã©ã¯ãŒãŒã·ã§ã³æ³ïŒæ·±åŒåžãçæ³ãªã©ïŒãè¶£å³ã®æéãå人ãšã®äº€æµãªã©ãéããŠãã¹ãã¬ã¹ãé©åã«ç®¡çããŸãããã
- 瀟äŒçãªã€ãªãããç¶æããïŒäººãšã®äº€æµã¯ãè³ãåºæ¿ãã粟ç¥çãªå¥åº·ãä¿ã€äžã§éèŠã§ããå®¶æãå人ãšã®ã³ãã¥ãã±ãŒã·ã§ã³ã倧åã«ããç€ŸäŒæŽ»åã«ç©æ¥µçã«åå ããŸãããã
- ç°å€ãæãããå°éå®¶ãžçžè«ïŒãããæèåã®äœäžãç©å¿ããéäžåã®æ¬ åŠãªã©ãç¶ããæ¥åžžçæŽ»ã«æ¯éããããããã§ããã°ããããã€ãå»ãç¥çµå ç§ã粟ç¥ç§ãªã©ã®å°éå»ã«çžè«ããŸããããæ©æã«é©åãªèšºæãšã¢ããã€ã¹ãåããããšã倧åã§ãã
â ïžç ç©¶ã®éçãšä»åŸã®èª²é¡
æ¬ç ç©¶ã¯å€§èŠæš¡ãªãªã³ã©ã€ã³èª¿æ»ã§ãããäžåœã«ãããCOVID-19åŸã®èªç¥æ©èœã«é¢ãã貎éãªããŒã¿ãæäŸããŸããããããã€ãã®éçãååšããŸãã
- ãªã³ã©ã€ã³èª¿æ»ã®éçïŒèªå·±ç³åã«ããããŒã¿åéã®ãããåçã®æ£ç¢ºæ§ããã€ã¢ã¹ãå«ãŸããå¯èœæ§ããããŸãããŸãã詳现ãªå»åŠçæ å ±ïŒåºç€çŸæ£ãCOVID-19ã®éç床ãªã©ïŒãååã«åéã§ããŠããªãå¯èœæ§ããããŸãã
- å®¢èŠ³çæ€æ»ã®éçïŒäœ¿çšãããèªç¥æ©èœãã¹ãã¯ãã¹ã¯ãªãŒãã³ã°ã«ã¯é©ããŠããŸããããã詳现ãªèªç¥æ©èœã®åŽé¢ãè©äŸ¡ããã«ã¯ãããå°éçãªç¥çµå¿çåŠçæ€æ»ãå¿ èŠãšãªãå ŽåããããŸãã
- ãäºæ¥æ§æãã«éå®ïŒçºçåŸ3ã¶ææªæºã®æéã«çŠç¹ãåœãŠãŠãããããCOVID-19åŸã®èªç¥æ©èœã®é·æçãªå€åã«ã€ããŠã¯ããã®ç ç©¶ããã¯åãããŸããã
- äžåœãšããç¹å®ã®å°åïŒç ç©¶çµæã¯äžåœã®ç¹å®ã®æåã»ç€ŸäŒèæ¯ãæã€äººã ã«éå®ããããããä»ã®åœãå°åã®äººã ã«ãã®ãŸãŸåœãŠã¯ãŸããšã¯éããŸããã
ä»åŸã®ç ç©¶ã§ã¯ããããã®éçãå æãããã詳现ãªèšåºããŒã¿ã«åºã¥ããé·æçãªè¿œè·¡èª¿æ»ãã倿§ãªèªç¥æ©èœãã¹ããçšããå€è§çãªè©äŸ¡ãæ±ããããŸãããŸããè匱ãªãµãã°ã«ãŒãã«å¯Ÿããåå¥åãããä»å ¥æ¹æ³ã®éçºãéèŠãªèª²é¡ãšãªãã§ãããã
ä»åã®äžåœã«ãããç ç©¶ã¯ãCOVID-19åŸã®èªç¥æ©èœã®èª²é¡ãã䞻芳çãªèšŽããšããŠéåžžã«å€ãååšããç¹ã«å¥³æ§ãé«éœ¢è ãäœåŠæŽè ããããŠäžç çãæ±ãã人ã ããã®åœ±é¿ãåããããããšã瀺ããŸããã客芳çãªåœ±é¿ã¯è»œåŸ®ã§ãããã®ã®ãå人ã®ç掻ã®è³ªã«äžãã圱é¿ã¯ç¡èŠã§ããŸãããç§ãã¡ã¯ããã®ç ç©¶çµæãåèã«ãèªèº«ã®å¥åº·ç®¡çã«åªãããšãšãã«ãã³ããåŸã®ç€ŸäŒã«ãããèªç¥æ©èœã®èª²é¡ã«å¯Ÿããããçè§£ãæ·±ããé©åãªãµããŒãäœå¶ãæ§ç¯ããŠããå¿ èŠããããŸãã
é¢é£ãªã³ã¯é
- åçåŽåç
- åœç«ç²Ÿç¥ã»ç¥çµå»çç ç©¶ã»ã³ã¿ãŒ
- æ¥æ¬ç¥çµåŠäŒ
- äžçä¿å¥æ©é¢ïŒWHOïŒ
- PubMed (è«ææ€çŽ¢ããŒã¿ããŒã¹)
æžèªæ å ±
| DOI | 10.1631/jzus.B2500553 |
|---|---|
| PMID | 42806849 |
| PubMed URL | https://pubmed.ncbi.nlm.nih.gov/42806849/ |
| çºè¡å¹Ž | 2026 |
| èè å | Luo Xue, Zeng Shufei, Liu Shuai, Li Yuanhui, Fang Leqin, Li Dai, Xin Qianqian, DU Shixu, Xu Yan, Zhang Bin |
| èè æå± | Department of Psychiatry, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.; Adai Technology (Beijing) Company Limited, Beijing 100123, China.; Department of Psychiatry, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. zhang73bin@hotmail.com. |
| éèªå | J Zhejiang Univ Sci B |